American Journal of Ophthalmology
Volume 139, Issue 3 , Pages 468-475, March 2005

Iris melanocytoma: Clinical features and natural course in 47 cases

Presented in part at the annual meeting of The Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida, May 2003 (H.D.) and at the annual meeting of American Academy of Ophthalmology, New Orleans, Louisiana, October, 2004 (H.D.).

  • Hakan Demirci, MD

      Affiliations

    • Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • ,
  • Arman Mashayekhi, MD

      Affiliations

    • Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • ,
  • Carol L. Shields, MD

      Affiliations

    • Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
    • Corresponding Author InformationInquiries to Carol L. Shields, MD Oncology Service, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA 19107; fax: 215-928-1140
  • ,
  • Ralph C. Eagle Jr, MD

      Affiliations

    • Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • ,
  • Jerry A. Shields, MD

      Affiliations

    • Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.

Accepted 4 October 2004. published online 09 February 2005.

Purpose

To describe the clinical features, natural course, management and histopathologic features of iris melanocytoma.

Design

Single-center retrospective case series.

Methods

patient population: Forty-seven consecutive patients (47 eyes) with iris melanocytoma. intervention procedure: Data regarding patient and tumor features were analyzed for their impact on the main outcome measures using univariate and multivariate regression models. Kaplan-Meier estimates were used to analyze the main outcomes as a function of time. main outcome measures: Increased intraocular pressure (IOP), tumor seeding, and tumor growth.

Results

Associated findings at initial presentation included iris stromal seeds in 20 patients (43%), and anterior chamber angle seeds in 12 (26%). Intrinsic vascularization and sector cataract were not seen in any eyes. The management at presentation included observation in 39 patients (83%), tumor removal by sector iridectomy/iridocyclectomy in 7 (15%), and enucleation for blind painful eye with secondary increased IOP in 1 (2%). The diagnosis was confirmed by histopathologic examination in 11 patients (23%). The mean follow-up was 58 months. Using Kaplan-Meier estimates, clinical evidence of growth was observed in 23% at 5 years, 48% at 10 years, and 74% at 15 years. New tumor seeds developed in 34% at 5 years, 63% at 10 years, and 75% at 15 years. Increased IOP was observed in 11% at 5 years, 11% at 10 years, and 55% at 15 years.

Conclusions

Iris melanocytoma represented only 3% of all iris nevi. Related iris stromal and anterior chamber angle seeds were common, and secondary glaucoma occurred in 11% at 5 years. Growth was observed in 23% at 5 years but no malignant transformation was found.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Support provided by the International Award of Merit in Retina Research, Houston, Texas (J.A.S.), Rosenthal Award of the Macula Society (C.L.S.), Macula Foundation, New York, New York (C.L.S.), the Noel T. and Sara L. Simmonds Endowment for Ophthalmic Pathology, Wills Eye Hospital (R.C.E., Jr.) and the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (C.L.S., J.A.S.).

PII: S0002-9394(04)01246-2

doi:10.1016/j.ajo.2004.10.008

American Journal of Ophthalmology
Volume 139, Issue 3 , Pages 468-475, March 2005